calendar

5 catalysts · 5 approval

next 91 dayslessmore

MonWedFri

view

sort

type

therapy area

no tagged catalysts yet

Week of Apr 4, 2022

›Apr 5, 2022approval1589d agoIRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

Sponsor: HIKMA. Form: TABLET. Route: ORAL

›Apr 5, 2022approval1589d agoIRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

Sponsor: HIKMA. Form: TABLET. Route: ORAL

›Apr 5, 2022approval1589d agoIRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

›Apr 5, 2022approval1589d agoIRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

›Apr 5, 2022approval1589d agoIGALMI (DEXMEDETOMIDINE HYDROCHLORIDE) — FDA approvaldexmedetomidine

Sponsor: BIOXCEL. Form: FILM. Route: BUCCAL, SUBLINGUAL

$BTAI0.9215-10.53%